The Omega TB software delivers a comprehensive clinical report covering resistance to 18 anti-TB drugs
HaystackAnalytics has introduced ‘TB One,’ a Make-in-India solution designed to enhance TB diagnosis by enabling Next-Generation Sequencing (NGS) at any diagnostic lab or hospital. This all-in-one offering includes a pre-sequencing kit for Whole Genome Sequencing (WGS), access to ‘Omega TB’—HaystackAnalytics’ patented clinical reporting software—and on-demand access to 2GB of sequencing data.
The Omega TB software delivers a comprehensive clinical report covering resistance to 18 anti-TB drugs, along with mixed infections, non-tuberculous mycobacteria (NTM), and heteroresistance—all within a single, standardized report. By equipping healthcare providers with precise, data-driven insights, ‘TB One’ aims to improve TB management and strengthen India’s fight against the disease.
The Solution has been unvieled by Dr Anirvan Chatterjee, Co-founder and CEO, HaystackAnalytics & Dr Rajendra Prasad at the Indian Council of Medical Research's (ICMR) India Innovation Summit: Pioneering Solutions to End TB on March 19, 2025. With this solution genomics-based TB testing would become more accessible and scalable by enabling existing laboratories to upgrade to NGS testing for TB without significant infrastructure changes. This solution aligns seamlessly with HaystackAnalytics' mission to make genomics accessible, applicable, and affordable, addressing a critical need to transform molecular diagnostic laboratories into advanced genomic facilities.
Dr Anirvan Chatterjee, Co-founder and CEO, HaystackAnalytics, said, “We are empowering existing molecular labs to perform high-precision genomic testing without requiring expensive infrastructure modifications. This cost-effective and scalable approach ensures greater accessibility to advanced TB diagnostics across India. Each TB One kit contains reagents to process 16 samples and requires prior extraction of TB DNA. It seamlessly integrates into existing molecular workflows, facilitating efficient TB genomic sequencing.”
